Correlation Between NewAmsterdam Pharma and Citius Oncology,
Can any of the company-specific risk be diversified away by investing in both NewAmsterdam Pharma and Citius Oncology, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NewAmsterdam Pharma and Citius Oncology, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NewAmsterdam Pharma and Citius Oncology,, you can compare the effects of market volatilities on NewAmsterdam Pharma and Citius Oncology, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NewAmsterdam Pharma with a short position of Citius Oncology,. Check out your portfolio center. Please also check ongoing floating volatility patterns of NewAmsterdam Pharma and Citius Oncology,.
Diversification Opportunities for NewAmsterdam Pharma and Citius Oncology,
-0.61 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between NewAmsterdam and Citius is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding NewAmsterdam Pharma and Citius Oncology, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Citius Oncology, and NewAmsterdam Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NewAmsterdam Pharma are associated (or correlated) with Citius Oncology,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Citius Oncology, has no effect on the direction of NewAmsterdam Pharma i.e., NewAmsterdam Pharma and Citius Oncology, go up and down completely randomly.
Pair Corralation between NewAmsterdam Pharma and Citius Oncology,
Given the investment horizon of 90 days NewAmsterdam Pharma is expected to generate 0.28 times more return on investment than Citius Oncology,. However, NewAmsterdam Pharma is 3.59 times less risky than Citius Oncology,. It trades about 0.03 of its potential returns per unit of risk. Citius Oncology, is currently generating about -0.2 per unit of risk. If you would invest 1,892 in NewAmsterdam Pharma on September 1, 2024 and sell it today you would earn a total of 93.00 from holding NewAmsterdam Pharma or generate 4.92% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 61.9% |
| Values | Daily Returns |
NewAmsterdam Pharma vs. Citius Oncology,
Performance |
| Timeline |
| NewAmsterdam Pharma |
| Citius Oncology, |
NewAmsterdam Pharma and Citius Oncology, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with NewAmsterdam Pharma and Citius Oncology,
The main advantage of trading using opposite NewAmsterdam Pharma and Citius Oncology, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NewAmsterdam Pharma position performs unexpectedly, Citius Oncology, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will offset losses from the drop in Citius Oncology,'s long position.| NewAmsterdam Pharma vs. Monte Rosa Therapeutics | NewAmsterdam Pharma vs. Inventiva Sa | NewAmsterdam Pharma vs. Cullinan Oncology LLC | NewAmsterdam Pharma vs. Compass Therapeutics |
| Citius Oncology, vs. Verve Therapeutics | Citius Oncology, vs. Beam Therapeutics | Citius Oncology, vs. Caribou Biosciences | Citius Oncology, vs. Sana Biotechnology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Complementary Tools
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |